Processing

Please wait...

Settings

Settings

1. WO1996003152 - ANTISENSE OLIGONUCLEOTIDES AGAINST HEPATITIS B VIRAL REPLICATION

Publication Number WO/1996/003152
Publication Date 08.02.1996
International Application No. PCT/US1995/009143
International Filing Date 28.07.1995
Chapter 2 Demand Filed 28.02.1996
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C12N 15/11 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C12N 15/1131
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
1131against viruses
C12N 2310/3125
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
31of the backbone
312Phosphonates
3125Methylphosphonates
C12N 2310/315
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
31of the backbone
315Phosphorothioates
Applicants
  • GEORGETOWN UNIVERSITY [US/US]; Ryan Administration Building 37th and 0 Streets, N.W. Washington, DC 20057, US
Inventors
  • KORBA, Brent, E.; US
  • GERIN, John, L.; US
Agents
  • BENT, Stephen, A. ; Foley & Lardner Suite 500 3000 K Street, N.W. Washington, DC 20007-5109, US
Priority Data
08/281,10628.07.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTISENSE OLIGONUCLEOTIDES AGAINST HEPATITIS B VIRAL REPLICATION
(FR) OLIGONUCLEOTIDES ANTISENS CONTRE LA REPLICATION VIRALE DE L'HEPATITE B
Abstract
(EN)
Antisense oligonucleotides that hybridize to segments of the preS1, S, C, and epsilon regions of the hepatitis B virus (HBV) RNA pregenome inhibit replication of the virus. The figure illustrates the relative positions of antisense oligonucleotides targeted against the HBV S gene. Pharmaceutical compositions which contain these oligonucleotides as the active ingredients are effective against HBV infection.
(FR)
Des oligonucléotides antisens s'hybridant à des segments des régions preS1, S, C et epsilon du prégénome de l'ARN du virus de l'hépatite B (HBV) inhibent la réplication de ce virus. La figure illustre les positions relatives d'oligonucléotides antisens ciblés contre le gène S de HBV. Des compositions pharmaceutiques contenant ces oligonucléotides en tant qu'ingrédients actifs sont efficaces contre l'infection par HBV.
Latest bibliographic data on file with the International Bureau